 Jeffrey Schowinsky
Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 8 | 2024 | 592 | 0.880 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 61 | 0.630 |
Why?
| | Brain Neoplasms | 3 | 2018 | 1143 | 0.590 |
Why?
| | Azacitidine | 4 | 2023 | 139 | 0.570 |
Why?
| | Lipomatosis | 1 | 2015 | 4 | 0.480 |
Why?
| | HMGA2 Protein | 1 | 2015 | 9 | 0.480 |
Why?
| | Adamantinoma | 1 | 2015 | 5 | 0.470 |
Why?
| | Synovial Membrane | 1 | 2015 | 90 | 0.450 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2017 | 758 | 0.430 |
Why?
| | Tibia | 1 | 2015 | 170 | 0.420 |
Why?
| | Eosinophilia | 1 | 2015 | 204 | 0.410 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2012 | 16 | 0.380 |
Why?
| | Skin Neoplasms | 2 | 2018 | 824 | 0.370 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2012 | 73 | 0.360 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 5 | 2023 | 215 | 0.310 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1555 | 0.310 |
Why?
| | Soft Tissue Neoplasms | 2 | 2023 | 111 | 0.300 |
Why?
| | Clonal Evolution | 2 | 2017 | 39 | 0.250 |
Why?
| | Biopsy, Needle | 1 | 2006 | 189 | 0.250 |
Why?
| | Diagnostic Errors | 1 | 2006 | 162 | 0.240 |
Why?
| | Rectum | 1 | 2006 | 170 | 0.230 |
Why?
| | Sulfonamides | 4 | 2021 | 495 | 0.230 |
Why?
| | Tissue Scaffolds | 1 | 2024 | 201 | 0.190 |
Why?
| | Carrier Proteins | 2 | 2017 | 742 | 0.190 |
Why?
| | Surgical Wound Infection | 1 | 2024 | 283 | 0.180 |
Why?
| | Nuclear Proteins | 2 | 2017 | 659 | 0.180 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.180 |
Why?
| | Mastocytosis | 1 | 2021 | 11 | 0.180 |
Why?
| | Keratins | 2 | 2015 | 175 | 0.170 |
Why?
| | Extracellular Matrix | 1 | 2024 | 502 | 0.170 |
Why?
| | Adenocarcinoma | 1 | 2006 | 898 | 0.160 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 1016 | 0.150 |
Why?
| | Fatal Outcome | 2 | 2018 | 299 | 0.150 |
Why?
| | Humans | 27 | 2024 | 129248 | 0.140 |
Why?
| | Pyrazoles | 2 | 2021 | 404 | 0.140 |
Why?
| | Fibromatosis, Aggressive | 1 | 2017 | 17 | 0.140 |
Why?
| | Tetrahydronaphthalenes | 1 | 2017 | 30 | 0.140 |
Why?
| | Leukemia, Neutrophilic, Chronic | 1 | 2017 | 5 | 0.140 |
Why?
| | Valine | 1 | 2017 | 81 | 0.140 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2017 | 6 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 38 | 0.140 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2017 | 79 | 0.130 |
Why?
| | Biomarkers, Tumor | 2 | 2018 | 1173 | 0.130 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2016 | 6 | 0.130 |
Why?
| | Genetic Association Studies | 1 | 2018 | 361 | 0.130 |
Why?
| | Mutation | 3 | 2017 | 3710 | 0.130 |
Why?
| | Skull Base Neoplasms | 1 | 2016 | 25 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 4 | 2016 | 3386 | 0.130 |
Why?
| | Lymphoma | 1 | 2017 | 196 | 0.130 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 7 | 0.120 |
Why?
| | Leukocytosis | 1 | 2015 | 32 | 0.120 |
Why?
| | Gene Frequency | 1 | 2017 | 502 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 232 | 0.120 |
Why?
| | Neoplasm, Residual | 3 | 2023 | 120 | 0.120 |
Why?
| | Tenosynovitis | 1 | 2015 | 11 | 0.120 |
Why?
| | Lipoma | 1 | 2015 | 15 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 278 | 0.120 |
Why?
| | Natalizumab | 2 | 2012 | 40 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 756 | 0.120 |
Why?
| | Middle Aged | 8 | 2024 | 31087 | 0.110 |
Why?
| | Tissue Culture Techniques | 1 | 2013 | 74 | 0.110 |
Why?
| | Genomic Instability | 1 | 2013 | 48 | 0.100 |
Why?
| | Induction Chemotherapy | 2 | 2024 | 70 | 0.100 |
Why?
| | Male | 13 | 2024 | 63501 | 0.100 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2012 | 18 | 0.100 |
Why?
| | Membrane Glycoproteins | 1 | 2015 | 476 | 0.100 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2012 | 37 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2018 | 327 | 0.090 |
Why?
| | CD3 Complex | 1 | 2012 | 103 | 0.090 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 108 | 0.090 |
Why?
| | Prognosis | 4 | 2024 | 3772 | 0.090 |
Why?
| | Female | 13 | 2024 | 68543 | 0.090 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1691 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1367 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 958 | 0.090 |
Why?
| | Immunologic Factors | 1 | 2012 | 230 | 0.080 |
Why?
| | Leukocyte Count | 2 | 2024 | 326 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2015 | 352 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1207 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2276 | 0.080 |
Why?
| | Antineoplastic Agents | 2 | 2017 | 2053 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2015 | 1117 | 0.070 |
Why?
| | Bone Marrow | 3 | 2017 | 271 | 0.070 |
Why?
| | Lymphatic Diseases | 1 | 2008 | 21 | 0.070 |
Why?
| | Adult | 8 | 2024 | 35495 | 0.070 |
Why?
| | Neutropenia | 1 | 2008 | 136 | 0.070 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2007 | 55 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2024 | 14455 | 0.070 |
Why?
| | Racemases and Epimerases | 1 | 2006 | 11 | 0.070 |
Why?
| | Aged | 6 | 2024 | 22032 | 0.070 |
Why?
| | Chromosome Aberrations | 2 | 2018 | 148 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2515 | 0.060 |
Why?
| | Mucins | 1 | 2006 | 70 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2024 | 10199 | 0.060 |
Why?
| | Prostate-Specific Antigen | 1 | 2006 | 162 | 0.060 |
Why?
| | Diagnosis, Differential | 2 | 2007 | 1430 | 0.060 |
Why?
| | Carcinoma, Renal Cell | 1 | 2007 | 180 | 0.060 |
Why?
| | Hyphae | 1 | 2024 | 11 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2021 | 7055 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 88 | 0.050 |
Why?
| | Biopsy | 2 | 2018 | 1091 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 348 | 0.050 |
Why?
| | Fungi | 1 | 2024 | 135 | 0.050 |
Why?
| | Cytodiagnosis | 1 | 2023 | 32 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 1 | 2023 | 68 | 0.050 |
Why?
| | Disease Progression | 2 | 2023 | 2630 | 0.050 |
Why?
| | World Health Organization | 1 | 2023 | 110 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2007 | 640 | 0.050 |
Why?
| | Wound Healing | 1 | 2024 | 305 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2006 | 589 | 0.050 |
Why?
| | Triazines | 1 | 2021 | 38 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2018 | 1155 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 12388 | 0.040 |
Why?
| | Pyrroles | 1 | 2021 | 202 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4886 | 0.040 |
Why?
| | Neoplastic Stem Cells | 1 | 2023 | 379 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 271 | 0.040 |
Why?
| | Karyotyping | 1 | 2018 | 107 | 0.040 |
Why?
| | Histocytochemistry | 1 | 2018 | 82 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 572 | 0.040 |
Why?
| | Genetic Testing | 1 | 2019 | 428 | 0.030 |
Why?
| | Temporomandibular Joint | 1 | 2016 | 8 | 0.030 |
Why?
| | Frontal Bone | 1 | 2016 | 12 | 0.030 |
Why?
| | Cranial Fossa, Middle | 1 | 2016 | 7 | 0.030 |
Why?
| | Occipital Bone | 1 | 2016 | 18 | 0.030 |
Why?
| | Sphenoid Bone | 1 | 2016 | 15 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 172 | 0.030 |
Why?
| | Temporal Bone | 1 | 2016 | 49 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 286 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 208 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 785 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 313 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 385 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1005 | 0.030 |
Why?
| | Karyotype | 1 | 2013 | 17 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1018 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 459 | 0.030 |
Why?
| | Heterografts | 1 | 2013 | 131 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 256 | 0.030 |
Why?
| | Chondrogenesis | 1 | 2013 | 82 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2013 | 302 | 0.020 |
Why?
| | Carcinogenesis | 1 | 2013 | 213 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 682 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2017 | 890 | 0.020 |
Why?
| | Infant | 2 | 2018 | 8975 | 0.020 |
Why?
| | Genetic Variation | 1 | 2013 | 938 | 0.020 |
Why?
| | Leukocyte Elastase | 1 | 2008 | 74 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2013 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6543 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 436 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 857 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3201 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2374 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1887 | 0.020 |
Why?
| | Brain | 1 | 2012 | 2669 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 20303 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2008 | 5736 | 0.010 |
Why?
| | Mice | 1 | 2013 | 16915 | 0.010 |
Why?
| | Animals | 1 | 2013 | 35307 | 0.010 |
Why?
| | Child | 1 | 2008 | 20773 | 0.000 |
Why?
|
|
Schowinsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|